Daniel P Petrylak
Overview
Explore the profile of Daniel P Petrylak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
13697
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401283.
PMID: 40043230
Purpose: The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov...
2.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
3.
Petrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, et al.
J Clin Oncol
. 2024 Aug;
42(29):3410-3420.
PMID: 39186707
Purpose: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based...
4.
de Wit R, Vaughn D, Fradet Y, Fong L, Climent M, Necchi A, et al.
Eur Urol
. 2024 Aug;
PMID: 39174409
Background And Objective: Until recently, the standard first-line treatment for advanced urothelial carcinoma (UC) was platinum-based combination chemotherapy followed by avelumab maintenance therapy for patients without progressive disease (PD). For...
5.
Loriot Y, Balar A, Petrylak D, Kalebasty A, Grivas P, Flechon A, et al.
Clin Cancer Res
. 2024 Aug;
30(15):3179-3188.
PMID: 39086310
Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker...
6.
Grant M, Stockhammer P, Austin M, Nemeth Z, Petrylak D
Bladder Cancer
. 2024 Jul;
10(1):9-23.
PMID: 38993528
Introduction: Antibody drug conjugates represent a promising class of antineoplastic agents comprised of a monoclonal antibody linked to a potent cytotoxic payload for targeted delivery of chemotherapy to tumors. Various...
7.
Bryce A, Crawford E, Agarwal N, Hussain M, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774467
Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are...
8.
Crawford E, Bryce A, Hussain M, Agarwal N, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774466
Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions...
9.
Rosenberg J, Mamtani R, Sonpavde G, Loriot Y, Duran I, Lee J, et al.
Eur Urol
. 2024 Feb;
85(6):574-585.
PMID: 38418343
Background And Objective: In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was...
10.
Grivas P, Pouessel D, Park C, Barthelemy P, Bupathi M, Petrylak D, et al.
J Clin Oncol
. 2024 Jan;
42(12):1415-1425.
PMID: 38261969
Purpose: Pembrolizumab is standard therapy for patients with metastatic urothelial cancer (mUC) who progress after first-line platinum-based chemotherapy; however, only approximately 21% of patients respond. Sacituzumab govitecan (SG) is a...